This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • General Rhinology  • Alert me on articles by topic  Social Bookmarking   What's this?

Sandeep Bhatia, BS; Fuad M. Baroody, MD; Marcy deTineo, BSN; Robert M. Naclerio, MD

Arch Otolaryngol Head Neck Surg. 2005;131:223-228.

Objective  To compare the effects of desloratadine, an H₁-blocking antihistamine, and budesonide, an intranasal corticosteroid, on nasal peak inspiratory flow (NPIF) in patients with seasonal allergic rhinitis.

Design  We performed a randomized, double-blind, double-dummy, parallel study comparing oral desloratadine, 5 mg/d (n = 31), and budesonide, 32 µg/d per nostril (n = 30), for 2 weeks during the spring allergy season.

Main Outcome Measures  Subjects recorded NPIF and nasal symptoms twice daily. Baseline measurements were obtained before initiation of treatment. The Rhinoconjunctivitis Quality of Life Questionnaire was completed at baseline and after treatment.

Results  Desloratadine and budesonide caused a significant increase in NPIF compared with baseline on the evening of the first dose (P<.01). Budesonide, however, led to a significantly greater increase in NPIF than did desloratadine when the change from baseline was compared for the entire treatment period (median, 475 vs 150 L/min; P = .01). Both treatments resulted in clinically significant reductions of the individual domains and overall scores on the Rhinoconjunctivitis Quality of Life Questionnaire (P<.01). There was a significant reduction in total symptom scores (P.01) compared with baseline during all treatment days in both treatment groups, with no statistically significant differences between treatments (median, –60.0 vs –59.5; P = .67).

Conclusions  Both treatments led to significant improvements in NPIF, but the improvement was greater with the intranasal corticosteroid. Both treatments improved quality of life and reduced symptoms. The difference between the objective and subjective outcomes probably reflects the small sample size, the low pollen counts for the season, and the greater variability in subjective compared with objective measures.

Author Affiliations: Section of Otolaryngology–Head and Neck Surgery, The Pritzker School of Medicine, University of Chicago, Chicago, Ill.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Comparison of montelukast and pseudoephedrine in the treatment of allergic rhinitis.
Mucha et al.
Arch Otolaryngol Head Neck Surg 2006;132:164-172.
ABSTRACT | FULL TEXT